'Game changer' diabetes pill a step closer after trials
That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar.
Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine.
"It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP.
"The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro."
The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend.
Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns.
The trial focused on diabetes treatment and not specifically weight loss.
Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said.
He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro.
The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments.
"These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said.
"In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world."
Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections.
While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar.
"As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said.
Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug.
Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues.
That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar.
Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine.
"It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP.
"The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro."
The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend.
Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns.
The trial focused on diabetes treatment and not specifically weight loss.
Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said.
He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro.
The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments.
"These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said.
"In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world."
Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections.
While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar.
"As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said.
Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug.
Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues.
That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar.
Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine.
"It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP.
"The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro."
The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend.
Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns.
The trial focused on diabetes treatment and not specifically weight loss.
Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said.
He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro.
The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments.
"These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said.
"In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world."
Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections.
While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar.
"As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said.
Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug.
Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues.
That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar.
Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine.
"It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP.
"The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro."
The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend.
Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns.
The trial focused on diabetes treatment and not specifically weight loss.
Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said.
He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro.
The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments.
"These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said.
"In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world."
Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections.
While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar.
"As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said.
Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Advertiser
3 hours ago
- The Advertiser
'Invariably fatal' rare bat virus claims another victim
A man has died after contracting an extremely rare, rabies-like bat virus, the fourth death since its discovery almost 30 years ago. NSW Health confirmed the man in his 50s died on Thursday after being bitten by a bat several months ago. The northern NSW man was the first recorded case of Australian bat lyssavirus in the state and only the fourth in the nation. Lyssavirus transmits from infected bats to humans when virus in their saliva enters the body through a bite or scratch. Emerging bat viruses expert Alison Peel told AAP the virus, like rabies, travels through the nervous system to the brain. "That happens very slowly so it's quite usual for that to take a number of months between the exposure and the clinical signs developing," the University of Sydney Horizon Fellow said. More than 100 people received medical treatment after potential or suspected exposures each year, Dr Peel said, but it was unknown how many actually contracted the virus. "But certainly, once clinical signs develop ... it's generally, invariably fatal." Australia is home to more than 80 species of bats, and without widespread surveillance of them all, it's safest to assume any bat could be carrying the virus. It was only transmitted through direct contact, so being near bats, or even pooed on by one, was not cause for too much alarm, Dr Peel said. "It's an important consideration to try and avoid direct contact and not touching bats, but we shouldn't panic and take it out on the bats themselves." The virus is also potentially deadly to bats. "It does seem to be circulating within their populations at very, very low levels," Dr Peel said. "But there are quite a high proportion of bats out there that have antibody evidence that suggests that they have been exposed to the virus in the past and they've not become sick. "There is something unique about the way bats are able to handle the infection." It is extremely rare for the virus to transmit to humans because it does not spread through the air. A NSW Health spokesman said anyone bitten or scratched by a bat should seek urgent medical assessment. "Only wildlife handlers who are trained, protected, and vaccinated should interact with bats." People bitten or scratched by a bat require rabies immunoglobulin and rabies vaccine. In 2024, 118 people were treated after being bitten or scratched by a bat around the nation. The virus was first discovered in a black flying fox in Queensland in 1996. A man has died after contracting an extremely rare, rabies-like bat virus, the fourth death since its discovery almost 30 years ago. NSW Health confirmed the man in his 50s died on Thursday after being bitten by a bat several months ago. The northern NSW man was the first recorded case of Australian bat lyssavirus in the state and only the fourth in the nation. Lyssavirus transmits from infected bats to humans when virus in their saliva enters the body through a bite or scratch. Emerging bat viruses expert Alison Peel told AAP the virus, like rabies, travels through the nervous system to the brain. "That happens very slowly so it's quite usual for that to take a number of months between the exposure and the clinical signs developing," the University of Sydney Horizon Fellow said. More than 100 people received medical treatment after potential or suspected exposures each year, Dr Peel said, but it was unknown how many actually contracted the virus. "But certainly, once clinical signs develop ... it's generally, invariably fatal." Australia is home to more than 80 species of bats, and without widespread surveillance of them all, it's safest to assume any bat could be carrying the virus. It was only transmitted through direct contact, so being near bats, or even pooed on by one, was not cause for too much alarm, Dr Peel said. "It's an important consideration to try and avoid direct contact and not touching bats, but we shouldn't panic and take it out on the bats themselves." The virus is also potentially deadly to bats. "It does seem to be circulating within their populations at very, very low levels," Dr Peel said. "But there are quite a high proportion of bats out there that have antibody evidence that suggests that they have been exposed to the virus in the past and they've not become sick. "There is something unique about the way bats are able to handle the infection." It is extremely rare for the virus to transmit to humans because it does not spread through the air. A NSW Health spokesman said anyone bitten or scratched by a bat should seek urgent medical assessment. "Only wildlife handlers who are trained, protected, and vaccinated should interact with bats." People bitten or scratched by a bat require rabies immunoglobulin and rabies vaccine. In 2024, 118 people were treated after being bitten or scratched by a bat around the nation. The virus was first discovered in a black flying fox in Queensland in 1996. A man has died after contracting an extremely rare, rabies-like bat virus, the fourth death since its discovery almost 30 years ago. NSW Health confirmed the man in his 50s died on Thursday after being bitten by a bat several months ago. The northern NSW man was the first recorded case of Australian bat lyssavirus in the state and only the fourth in the nation. Lyssavirus transmits from infected bats to humans when virus in their saliva enters the body through a bite or scratch. Emerging bat viruses expert Alison Peel told AAP the virus, like rabies, travels through the nervous system to the brain. "That happens very slowly so it's quite usual for that to take a number of months between the exposure and the clinical signs developing," the University of Sydney Horizon Fellow said. More than 100 people received medical treatment after potential or suspected exposures each year, Dr Peel said, but it was unknown how many actually contracted the virus. "But certainly, once clinical signs develop ... it's generally, invariably fatal." Australia is home to more than 80 species of bats, and without widespread surveillance of them all, it's safest to assume any bat could be carrying the virus. It was only transmitted through direct contact, so being near bats, or even pooed on by one, was not cause for too much alarm, Dr Peel said. "It's an important consideration to try and avoid direct contact and not touching bats, but we shouldn't panic and take it out on the bats themselves." The virus is also potentially deadly to bats. "It does seem to be circulating within their populations at very, very low levels," Dr Peel said. "But there are quite a high proportion of bats out there that have antibody evidence that suggests that they have been exposed to the virus in the past and they've not become sick. "There is something unique about the way bats are able to handle the infection." It is extremely rare for the virus to transmit to humans because it does not spread through the air. A NSW Health spokesman said anyone bitten or scratched by a bat should seek urgent medical assessment. "Only wildlife handlers who are trained, protected, and vaccinated should interact with bats." People bitten or scratched by a bat require rabies immunoglobulin and rabies vaccine. In 2024, 118 people were treated after being bitten or scratched by a bat around the nation. The virus was first discovered in a black flying fox in Queensland in 1996. A man has died after contracting an extremely rare, rabies-like bat virus, the fourth death since its discovery almost 30 years ago. NSW Health confirmed the man in his 50s died on Thursday after being bitten by a bat several months ago. The northern NSW man was the first recorded case of Australian bat lyssavirus in the state and only the fourth in the nation. Lyssavirus transmits from infected bats to humans when virus in their saliva enters the body through a bite or scratch. Emerging bat viruses expert Alison Peel told AAP the virus, like rabies, travels through the nervous system to the brain. "That happens very slowly so it's quite usual for that to take a number of months between the exposure and the clinical signs developing," the University of Sydney Horizon Fellow said. More than 100 people received medical treatment after potential or suspected exposures each year, Dr Peel said, but it was unknown how many actually contracted the virus. "But certainly, once clinical signs develop ... it's generally, invariably fatal." Australia is home to more than 80 species of bats, and without widespread surveillance of them all, it's safest to assume any bat could be carrying the virus. It was only transmitted through direct contact, so being near bats, or even pooed on by one, was not cause for too much alarm, Dr Peel said. "It's an important consideration to try and avoid direct contact and not touching bats, but we shouldn't panic and take it out on the bats themselves." The virus is also potentially deadly to bats. "It does seem to be circulating within their populations at very, very low levels," Dr Peel said. "But there are quite a high proportion of bats out there that have antibody evidence that suggests that they have been exposed to the virus in the past and they've not become sick. "There is something unique about the way bats are able to handle the infection." It is extremely rare for the virus to transmit to humans because it does not spread through the air. A NSW Health spokesman said anyone bitten or scratched by a bat should seek urgent medical assessment. "Only wildlife handlers who are trained, protected, and vaccinated should interact with bats." People bitten or scratched by a bat require rabies immunoglobulin and rabies vaccine. In 2024, 118 people were treated after being bitten or scratched by a bat around the nation. The virus was first discovered in a black flying fox in Queensland in 1996.
The Advertiser
3 hours ago
- The Advertiser
Dozens waiting for aid among 94 killed in Gaza
Air strikes and shootings have killed 94 Palestinians in Gaza overnight, including 45 who were attempting to get much-needed humanitarian aid, hospitals and the health ministry say. Israel's military did not immediately comment on the strikes. Five people were killed while outside sites associated with the Gaza Humanitarian Foundation, the newly created, secretive American organisation backed by Israel to feed the Gaza Strip's population, while 40 others were killed waiting for aid in other locations across the Gaza Strip. Dozens of people were killed in air strikes that pounded the Strip Wednesday night and Thursday morning, including 15 people killed in strikes that hit tents in the sprawling Muwasi zone, where many displaced Palestinians are sheltering. A separate strike on a school in Gaza City sheltering displaced people also killed 15 people. Gaza's health ministry said the number of Palestinians killed in Gaza had passed 57,000 since the war began on October 7, 2023. The toll includes 223 people who had been missing but have now been declared dead. The ministry does not differentiate between civilians and combatants in its death count but says that more than half of the dead are women and children. The deaths come as Israel and Hamas inch closer to a possible ceasefire that would end the 21-month war. Trump said Tuesday that Israel had agreed on terms for a 60-day ceasefire in Gaza and urged Hamas to accept the deal before conditions worsen. But Hamas's response, which emphasised its demand that the war end, raised questions about whether the latest offer could materialise into an actual pause in fighting. The Israeli military blames Hamas for the civilian casualties because it operates from populated areas. The military said it targeted Hamas militants and rocket launchers in northern Gaza that launched rockets toward Israel on Wednesday. The UK-based human rights group Amnesty International condemned both Israel and the Gaza Humanitarian Foundation, which the US and Israel have tapped to take over aid distribution in Gaza from a network led by the United Nations. The Amnesty report said Israel has "turned aid-seeking into a booby trap for desperate starved Palestinians" through GHF's militarised hubs. The conditions have created "a deadly mix of hunger and disease pushing the population past breaking point", it said. Israel's foreign minister denounced the Amnesty report, saying the organisation had "joined forces with Hamas and fully adopted all of its propaganda lies". Gaza's health ministry says more than 500 Palestinians have been killed at or near GHF distribution centres in the past month, including five overnight between Wednesday and Thursday in Khan Younis. The centres are guarded by private security contractors and located near Israeli military positions. Palestinian officials and witnesses have accused Israeli forces of opening fire at crowds of people moving near the sites. The war began when Hamas-led militants attacked southern Israel, killing 1200 people and taking about 250 hostages. The war has left the coastal Palestinian territory in ruins, with much of the urban landscape flattened in the fighting. More than 90 per cent of Gaza's 2.3 million population has been displaced, often multiple times. The war has sparked a humanitarian crisis in Gaza, leaving hundreds of thousands of people hungry. Air strikes and shootings have killed 94 Palestinians in Gaza overnight, including 45 who were attempting to get much-needed humanitarian aid, hospitals and the health ministry say. Israel's military did not immediately comment on the strikes. Five people were killed while outside sites associated with the Gaza Humanitarian Foundation, the newly created, secretive American organisation backed by Israel to feed the Gaza Strip's population, while 40 others were killed waiting for aid in other locations across the Gaza Strip. Dozens of people were killed in air strikes that pounded the Strip Wednesday night and Thursday morning, including 15 people killed in strikes that hit tents in the sprawling Muwasi zone, where many displaced Palestinians are sheltering. A separate strike on a school in Gaza City sheltering displaced people also killed 15 people. Gaza's health ministry said the number of Palestinians killed in Gaza had passed 57,000 since the war began on October 7, 2023. The toll includes 223 people who had been missing but have now been declared dead. The ministry does not differentiate between civilians and combatants in its death count but says that more than half of the dead are women and children. The deaths come as Israel and Hamas inch closer to a possible ceasefire that would end the 21-month war. Trump said Tuesday that Israel had agreed on terms for a 60-day ceasefire in Gaza and urged Hamas to accept the deal before conditions worsen. But Hamas's response, which emphasised its demand that the war end, raised questions about whether the latest offer could materialise into an actual pause in fighting. The Israeli military blames Hamas for the civilian casualties because it operates from populated areas. The military said it targeted Hamas militants and rocket launchers in northern Gaza that launched rockets toward Israel on Wednesday. The UK-based human rights group Amnesty International condemned both Israel and the Gaza Humanitarian Foundation, which the US and Israel have tapped to take over aid distribution in Gaza from a network led by the United Nations. The Amnesty report said Israel has "turned aid-seeking into a booby trap for desperate starved Palestinians" through GHF's militarised hubs. The conditions have created "a deadly mix of hunger and disease pushing the population past breaking point", it said. Israel's foreign minister denounced the Amnesty report, saying the organisation had "joined forces with Hamas and fully adopted all of its propaganda lies". Gaza's health ministry says more than 500 Palestinians have been killed at or near GHF distribution centres in the past month, including five overnight between Wednesday and Thursday in Khan Younis. The centres are guarded by private security contractors and located near Israeli military positions. Palestinian officials and witnesses have accused Israeli forces of opening fire at crowds of people moving near the sites. The war began when Hamas-led militants attacked southern Israel, killing 1200 people and taking about 250 hostages. The war has left the coastal Palestinian territory in ruins, with much of the urban landscape flattened in the fighting. More than 90 per cent of Gaza's 2.3 million population has been displaced, often multiple times. The war has sparked a humanitarian crisis in Gaza, leaving hundreds of thousands of people hungry. Air strikes and shootings have killed 94 Palestinians in Gaza overnight, including 45 who were attempting to get much-needed humanitarian aid, hospitals and the health ministry say. Israel's military did not immediately comment on the strikes. Five people were killed while outside sites associated with the Gaza Humanitarian Foundation, the newly created, secretive American organisation backed by Israel to feed the Gaza Strip's population, while 40 others were killed waiting for aid in other locations across the Gaza Strip. Dozens of people were killed in air strikes that pounded the Strip Wednesday night and Thursday morning, including 15 people killed in strikes that hit tents in the sprawling Muwasi zone, where many displaced Palestinians are sheltering. A separate strike on a school in Gaza City sheltering displaced people also killed 15 people. Gaza's health ministry said the number of Palestinians killed in Gaza had passed 57,000 since the war began on October 7, 2023. The toll includes 223 people who had been missing but have now been declared dead. The ministry does not differentiate between civilians and combatants in its death count but says that more than half of the dead are women and children. The deaths come as Israel and Hamas inch closer to a possible ceasefire that would end the 21-month war. Trump said Tuesday that Israel had agreed on terms for a 60-day ceasefire in Gaza and urged Hamas to accept the deal before conditions worsen. But Hamas's response, which emphasised its demand that the war end, raised questions about whether the latest offer could materialise into an actual pause in fighting. The Israeli military blames Hamas for the civilian casualties because it operates from populated areas. The military said it targeted Hamas militants and rocket launchers in northern Gaza that launched rockets toward Israel on Wednesday. The UK-based human rights group Amnesty International condemned both Israel and the Gaza Humanitarian Foundation, which the US and Israel have tapped to take over aid distribution in Gaza from a network led by the United Nations. The Amnesty report said Israel has "turned aid-seeking into a booby trap for desperate starved Palestinians" through GHF's militarised hubs. The conditions have created "a deadly mix of hunger and disease pushing the population past breaking point", it said. Israel's foreign minister denounced the Amnesty report, saying the organisation had "joined forces with Hamas and fully adopted all of its propaganda lies". Gaza's health ministry says more than 500 Palestinians have been killed at or near GHF distribution centres in the past month, including five overnight between Wednesday and Thursday in Khan Younis. The centres are guarded by private security contractors and located near Israeli military positions. Palestinian officials and witnesses have accused Israeli forces of opening fire at crowds of people moving near the sites. The war began when Hamas-led militants attacked southern Israel, killing 1200 people and taking about 250 hostages. The war has left the coastal Palestinian territory in ruins, with much of the urban landscape flattened in the fighting. More than 90 per cent of Gaza's 2.3 million population has been displaced, often multiple times. The war has sparked a humanitarian crisis in Gaza, leaving hundreds of thousands of people hungry. Air strikes and shootings have killed 94 Palestinians in Gaza overnight, including 45 who were attempting to get much-needed humanitarian aid, hospitals and the health ministry say. Israel's military did not immediately comment on the strikes. Five people were killed while outside sites associated with the Gaza Humanitarian Foundation, the newly created, secretive American organisation backed by Israel to feed the Gaza Strip's population, while 40 others were killed waiting for aid in other locations across the Gaza Strip. Dozens of people were killed in air strikes that pounded the Strip Wednesday night and Thursday morning, including 15 people killed in strikes that hit tents in the sprawling Muwasi zone, where many displaced Palestinians are sheltering. A separate strike on a school in Gaza City sheltering displaced people also killed 15 people. Gaza's health ministry said the number of Palestinians killed in Gaza had passed 57,000 since the war began on October 7, 2023. The toll includes 223 people who had been missing but have now been declared dead. The ministry does not differentiate between civilians and combatants in its death count but says that more than half of the dead are women and children. The deaths come as Israel and Hamas inch closer to a possible ceasefire that would end the 21-month war. Trump said Tuesday that Israel had agreed on terms for a 60-day ceasefire in Gaza and urged Hamas to accept the deal before conditions worsen. But Hamas's response, which emphasised its demand that the war end, raised questions about whether the latest offer could materialise into an actual pause in fighting. The Israeli military blames Hamas for the civilian casualties because it operates from populated areas. The military said it targeted Hamas militants and rocket launchers in northern Gaza that launched rockets toward Israel on Wednesday. The UK-based human rights group Amnesty International condemned both Israel and the Gaza Humanitarian Foundation, which the US and Israel have tapped to take over aid distribution in Gaza from a network led by the United Nations. The Amnesty report said Israel has "turned aid-seeking into a booby trap for desperate starved Palestinians" through GHF's militarised hubs. The conditions have created "a deadly mix of hunger and disease pushing the population past breaking point", it said. Israel's foreign minister denounced the Amnesty report, saying the organisation had "joined forces with Hamas and fully adopted all of its propaganda lies". Gaza's health ministry says more than 500 Palestinians have been killed at or near GHF distribution centres in the past month, including five overnight between Wednesday and Thursday in Khan Younis. The centres are guarded by private security contractors and located near Israeli military positions. Palestinian officials and witnesses have accused Israeli forces of opening fire at crowds of people moving near the sites. The war began when Hamas-led militants attacked southern Israel, killing 1200 people and taking about 250 hostages. The war has left the coastal Palestinian territory in ruins, with much of the urban landscape flattened in the fighting. More than 90 per cent of Gaza's 2.3 million population has been displaced, often multiple times. The war has sparked a humanitarian crisis in Gaza, leaving hundreds of thousands of people hungry.
9 News
7 hours ago
- 9 News
Ozempic-style drug ‘can provide migraine relief'
A small Italian study has found an Ozempic-style drug can halve the number of migraine days suffered in a month.
